Stifel on Olema Pharmaceuticals (OLMA): 'Investors Seeking Clarity on persevERA Miss'

March 16, 2026 10:14 AM

Stifel analyst Laura Prendergast reiterated a Buy rating and $48.00 price target on Olema Pharmaceuticals (NASDAQ: OLMA).The analyst comments "Today ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found